Malaysia's healthcare system is on the brink of a transformative shift, and one company is poised to ride the wave of modernization. But here's where it gets intriguing: RHB Small Cap Asean Research has just initiated coverage of LAC Med Bhd, labeling it a strategic player in Malaysia’s healthcare evolution. In their report, RHB predicts a 13% upside for the company, which made its debut on the Main Market of Bursa Malaysia in December 2025. So, what makes LAC Med stand out in this rapidly changing landscape? Let’s dive in.
LAC Med, Malaysia’s largest third-party medical equipment distributor, is uniquely positioned to capitalize on several key trends. These include the growing demand driven by hospital bed shortages, the rise in non-communicable diseases, an aging population, and the company’s ambitious expansion into Indonesia. And this is the part most people miss: with a 21-year track record and long-standing relationships, LAC Med has built a competitive moat that’s hard for rivals to breach. The company’s presence in 58% of Malaysian hospitals (217 facilities) and 832 clinics underscores its dominance in the market.
In the medical equipment sector, reliability isn’t just a perk—it’s a necessity. Equipment often lasts between eight to 12 years, requiring consistent long-term support. Yet, distribution agreements are typically short-term, and principals can terminate partnerships if performance falters. This makes LAC Med’s execution credibility a critical asset. In 2025, the company added five new principals, including industry giants like Abbott and Baxter, while strategically managing its product portfolio to avoid internal competition and maximize cross-selling opportunities.
Zooming out, Malaysia’s private healthcare sector is set for significant growth. By 2028, the number of private hospital beds is expected to rise from 18,800 in 2023 to 22,800, reflecting a 4% compound annual growth rate (CAGR). This expansion, driven by players like IHH Healthcare Bhd, KPJ Healthcare Bhd, and Sunway Healthcare Holdings Bhd, will fuel demand for medical equipment, diagnostics, and healthcare technology—all of which bodes well for distributors like LAC Med. Meanwhile, the public healthcare sector isn’t lagging behind, with a 7.8% CAGR in budget allocation from 2021 to 2026. Despite this progress, Malaysia’s healthcare spending remains below the OECD average, signaling ample room for growth.
Here’s where it gets controversial: LAC Med’s international ambitions are bold but not without risks. The company plans to invest RM8 million from its initial public offering proceeds to scale its Indonesian operations. While currently focused on a single principal, Alpinion, this segment is expected to significantly contribute to revenue by FY2026-FY2027, tapping into a market nearly eight times larger than Malaysia’s. However, diversifying beyond a single principal in Indonesia could be a double-edged sword—while it opens up opportunities, it also introduces complexities in a highly competitive market.
RHB forecasts LAC Med to achieve a three-year core earnings CAGR of 18.2% through FY2027, outpacing local competitors. Valued at a 15.7 times two-year forward price-earnings ratio, the company trades at a 34% premium to UMedic Group Bhd. But is this premium justified? RHB argues yes, citing three key reasons. First, LAC Med distributes established global brands like Philips and Samsung, which carry lower product and commercial risks compared to UMedic’s own-brand model. Second, LAC Med boasts a larger earnings base and stronger three-year earnings growth (18.2% vs. UMedic’s 13.6%). Third, LAC Med’s ability to undertake technically complex projects, such as those involving radioactive materials through its Atomic Energy Licensing Board (AELB) license, creates higher barriers to entry and supports more defensible earnings.
For FY2026, RHB projects a recurring net profit of RM29 million on RM288 million in turnover, supported by a robust order book of RM195.1 million, with RM128.4 million tied to complex supply and integration projects. As Malaysia’s largest authorized distributor of Philips medical equipment, LAC Med enjoys a de facto exclusive position due to Philips’ single-channel distribution model. However, this reliance on Philips (63% of purchases in FY2024) and potential project delays pose risks that investors should monitor.
As of Thursday’s midday break, LAC Med’s shares were up 4.66% to RM1.01, valuing the company at RM401.9 million. While the outlook is promising, the question remains: Can LAC Med sustain its growth trajectory in the face of regulatory changes and international expansion challenges? What’s your take? Do you see LAC Med as a frontrunner in Malaysia’s healthcare modernization, or are there risks that could derail its momentum? Share your thoughts in the comments below!
